

ASX Media Release



Intermediate Time Point in Large Animal Study Shows Positive Results

For Sr–HT–Gahnite Spinal Cage Device

SYDNEY January 31st 2022– Allegra Orthopaedics Limited (Allegra) (ASX: AMT) provides the following update on its flagship innovation project, the Sr–HT–Gahnite Spinal Cage Device (Spinal Cage):

Allegra is pleased to announce the large animal study performed at SAHMRI – PIRL (South Australian Health and Medical Research Institute – Preclinical, Imaging and Research Laboratories) has entered into its final stages with all animals implanted successfully.

SAHMRI is conducting the GLP, pre-clinical, cervical spinal fusion study in sheep for the interbody fusion Sr–HT–Gahnite Spinal Cage Device.

SAHMRI have commented that "the animals have coped well with the surgery. There have been no in-life complications associated with the procedures to date (18 weeks post-surgery).

Animals have been regularly CT-scanned to monitor the progression of the fusion site and all surgical sites are progressing well.

A 13-week cohort reached completion and no gross adverse biocompatibility issues have been observed. There was good evidence of fusion at the operated level"

In addition to CT scans, histological analyses will be performed following the completion of the in-life phase to provide further evidence of successful spinal fusion.

The completion of this study and the positive results being realized will confirm a viable pathway to obtaining a 90 day FDA 510(k) clearance in the near future in the United States.

Allegra Orthopaedics is the sole proprietor of the Sr-HT-Gahnite material and aims to apply the technology to fulfilling unmet needs across a broad range of applications including Spine, Hip & Knee and extremities.

Authorised by Jenny Swain, CEO.

Contact details: Justyn Stedwell – Company Secretary: T: 03 8395 5446



ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributors of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors.